Challenges and advances in CAR-T cell therapy for B-ALL.

Biomark Res · 2026 · PMC13330168 · PMID 42152081

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an important trendno p-value reported

Moving CAR-T therapy to earlier lines of B-ALL treatment Given the potent antileukemic activity of CAR‐T in R/R B‐ALL, moving CAR-T to earlier lines of treatment is an important trend.

also in 625 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.